Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNSP 
Cns Pharmaceuticals Inc (CNSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: CNSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $84
1 Year Target Price $84
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.09% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.51M USD | Price to earnings Ratio - | 1Y Target Price 84 |
Price to earnings Ratio - | 1Y Target Price 84 | ||
Volume (30-day avg) 2 | Beta 0.76 | 52 Weeks Range 6.28 - 121.74 | Updated Date 08/12/2025 |
52 Weeks Range 6.28 - 121.74 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -63.64 |
Earnings Date
Report Date 2025-08-13 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -127.31% | Return on Equity (TTM) -477.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -9324100 | Price to Sales(TTM) - |
Enterprise Value -9324100 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 529829 | Shares Floating 453597 |
Shares Outstanding 529829 | Shares Floating 453597 | ||
Percent Insiders 0.21 | Percent Institutions 1.29 |
Upturn AI SWOT
Cns Pharmaceuticals Inc
Company Overview
History and Background
CNS Pharmaceuticals, Inc. is a pharmaceutical company specializing in the development of novel treatments for primary and secondary brain cancers. Founded to address unmet needs in the treatment of central nervous system tumors, the company focuses on therapies that can cross the blood-brain barrier.
Core Business Areas
- Berubicin Development: Berubicin is CNS Pharmaceuticals' primary drug candidate, being developed for the treatment of glioblastoma multiforme (GBM) and other cancers affecting the brain and central nervous system.
- Preclinical Research: CNS Pharmaceuticals is engaged in preclinical research to discover and develop additional CNS-targeting therapies.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a board of directors providing oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Berubicin: Berubicin is an anthracycline being developed for GBM. Berubicin is in Phase II clinical trials. Competitors include Temozolomide, Bevacizumab, and other chemotherapies and targeted therapies for GBM. It is important to note that market share data related to the revenue/users or revenue from Berubicin is unknown as it is still in Phase II clinical trials.
Market Dynamics
Industry Overview
The pharmaceutical industry is focused on the development of treatments for cancers. The neuro-oncology market specifically addresses brain tumors and related conditions. The market is characterized by unmet medical needs and high research and development costs.
Positioning
CNS Pharmaceuticals is a clinical-stage company focused on developing innovative therapies for central nervous system tumors. Its competitive advantage lies in its targeted approach to delivering treatments across the blood-brain barrier.
Total Addressable Market (TAM)
The global brain tumor market is expected to reach approximately $3.5 Billion by 2030. CNS Pharmaceuticals aims to capture a portion of this market with Berubicin and future CNS-targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel CNS-targeting technology
- Experienced management team
- Clinical-stage drug candidate (Berubicin)
Weaknesses
- Reliance on a single drug candidate
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results for Berubicin
- Partnerships with larger pharmaceutical companies
- Expansion into other CNS indications
Threats
- Competition from established therapies
- Regulatory hurdles
- Failure to secure additional funding
Competitors and Market Share
Key Competitors
- MRK
- BMY
- Roche Holding AG (ROG.SW)
Competitive Landscape
CNS Pharmaceuticals faces competition from larger pharmaceutical companies with more resources and established products. Its competitive advantage lies in its focus on CNS-targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's stage of development. Growth is primarily related to advancing Berubicin through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of Berubicin.
Recent Initiatives: Recent initiatives include advancing Berubicin through clinical trials and securing funding for research and development.
Summary
CNS Pharmaceuticals is a development-stage company focusing on a significant unmet need in CNS cancers. Progressing Berubicin through clinical trials is crucial for its success. The company faces high risks associated with drug development and reliance on external funding. Positive clinical trial results would significantly improve its outlook, while failure could jeopardize its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and may vary based on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2019-11-08 | CEO, President & Director Mr. John Michael Climaco Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.cnspharma.com |
Full time employees 4 | Website https://www.cnspharma.com | ||
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.